1
|
Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa.
|
2015
|
3.30
|
2
|
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
|
2012
|
3.19
|
3
|
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
|
2012
|
3.15
|
4
|
2006 consensus guidelines for the management of women with abnormal cervical screening tests.
|
2007
|
3.11
|
5
|
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
|
2013
|
3.06
|
6
|
Use of CO2 laser vaporization for the treatment of high-grade vaginal intraepithelial neoplasia.
|
2013
|
2.63
|
7
|
Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents.
|
2004
|
2.24
|
8
|
Associations between religion-related factors and cervical cancer screening among Muslims in greater chicago.
|
2014
|
2.18
|
9
|
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
|
2013
|
2.18
|
10
|
Vulvar seborrheic keratosis: is there a relationship to human papillomavirus?
|
2014
|
2.14
|
11
|
Detection rates of trichomonas vaginalis, in different age groups, using real-time polymerase chain reaction.
|
2012
|
2.11
|
12
|
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women.
|
2010
|
2.03
|
13
|
Quantification of normal vaginal constituents using a new wet preparation technique.
|
2012
|
2.02
|
14
|
Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition.
|
2014
|
2.01
|
15
|
Utility of microscopic techniques and quantitative real-time polymerase chain reaction for the diagnosis of vaginal microflora alterations.
|
2015
|
1.99
|
16
|
eC3--a modern telecommunications matrix for cervical cancer prevention in Zambia.
|
2010
|
1.98
|
17
|
A clinicopathologic study of labia minora hypertrophy: signs of localized lymphedema were universal.
|
2014
|
1.98
|
18
|
Cervical cancer screening among immigrants and ethnic minorities: a systematic review using the Health Belief Model.
|
2008
|
1.92
|
19
|
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
|
2007
|
1.90
|
20
|
Evaluation of the VITOM in digital high-definition video exocolposcopy.
|
2011
|
1.87
|
21
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
|
2015
|
1.73
|
22
|
Knowledge and attitudes of adult peruvian women vis-à-vis Human Papillomavirus (HPV), cervical cancer, and the HPV vaccine.
|
2010
|
1.59
|
23
|
The vulvodynia guideline.
|
2005
|
1.55
|
24
|
A Randomized Trial of Human Papillomavirus Self-Sampling as an Intervention to Promote Cervical Cancer Screening Among Women With HIV.
|
2016
|
1.54
|
25
|
Review of terminology of precursors of vulvar squamous cell carcinoma.
|
2006
|
1.52
|
26
|
Spectroscopic imaging as a triage test for cervical disease: a prospective multicenter clinical trial.
|
2007
|
1.52
|
27
|
Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya.
|
2012
|
1.50
|
28
|
Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
|
2012
|
1.47
|
29
|
Management of vulvovaginal lichen planus: a new approach.
|
2013
|
1.45
|
30
|
Cytological evaluation correlates poorly with histological diagnosis of vulvar neoplasias.
|
2007
|
1.43
|
31
|
Communicating colposcopy results: what do patients and providers discuss?
|
2008
|
1.42
|
32
|
Evaluation of a low-cost liquid-based Pap test in rural El Salvador: a split-sample study.
|
2014
|
1.40
|
33
|
Endometrial cells in pap smears of postmenopausal women: cytohistologic correlation.
|
2003
|
1.40
|
34
|
Selecting Patients for Endocervical Curettage.
|
2015
|
1.40
|
35
|
Vulvar lichen sclerosus: a comparison of the short-term topical application of clobetasol dipropionate 0.05% versus mometasone furoate 0.1%.
|
2015
|
1.40
|
36
|
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy.
|
2015
|
1.39
|
37
|
Human papillomavirus vaccination: the policy debate over the prevention of cervical cancer--a commentary.
|
2008
|
1.38
|
38
|
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV.
|
2007
|
1.37
|
39
|
Umbilication is a strong predictor of high-grade cervical intraepithelial neoplasia.
|
2013
|
1.37
|
40
|
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
|
2013
|
1.36
|
41
|
Which Colposcopies Should Include Endocervical Curettage?
|
2015
|
1.36
|
42
|
Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey.
|
2013
|
1.30
|
43
|
Aggressive angiomyxoma of the vulva: a case report and review of the literature.
|
2009
|
1.29
|
44
|
The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia.
|
2009
|
1.28
|
45
|
Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
|
2013
|
1.27
|
46
|
Use of Smartphones as Adjuvant Tools for Cervical Cancer Screening in Low-Resource Settings.
|
2015
|
1.27
|
47
|
Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction.
|
2012
|
1.26
|
48
|
Pain at the vulvar vestibule: a web-based survey.
|
2004
|
1.25
|
49
|
Risk assessment to guide the prevention of cervical cancer.
|
2008
|
1.21
|
50
|
Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
|
2013
|
1.20
|